Acta Scientific MEDICAL SCIENCES (ISSN: 2582-0931)

Research Article Volume 6 Issue 10

Nicoletta Merli1, Paolo Lissoni1, Giuseppe Di Fede1, Marco Tornasi1, Dino Ceppodomo1 and Carlo Pastore2*

Nicoletta Merli1, Paolo Lissoni1, Giuseppe Di Fede1, Marco Tornasi1, Dino Ceppodomo1 and Carlo Pastore2*

1Institute of Biological Medicine, Milan, Italy 2Sanatrix Clinic, Oncological Department, Rome, Italy

*Corresponding Author: Carlo Pastore, Sanatrix Clinic, Oncological Department, Rome, Italy.

Received: July 18, 2022; Published: September 29, 2022

Abstract

Lymphocytopenia is something that cancer patients present with very often. Lymphocyte deficiency appears to be correlated with a worse prognosis. This experimental study emphasises how the combination of melatonin and AHCC in appropriate dosages can help counteract lymphopenia.

Keywords: Melatonin; Cancer; Lymphocytopenia; AHCC

References

  1. Hlubocky FJ., et al. “Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials”. Journal of Clinical Oncology 25 (2007): 548-554.
  2. Reiter RJ. “Mechanisms of cancer inhibition by melatonin”. Journal of Pineal Research 37 (2004): 213-214.
  3. Bartsch C and Bartsch H. “Melatonin in cancer patients and in tumor-bearing animals”. Advances in Experimental Medicine and Biology 467 (1999): 247-264.
  4. Lissoni P. “The pineal gland as a centrai regulator of cytokine network”. Neuroendocrinology Letter 20 (1999): 343-349.
  5. Pastore C. “Treatment of Platelet Deficiency in a Cohort of Patients by a Combination of Melatonin and 5-Methoxytryptamine". Acta Scientific Medical Sciences7 (2021): 66-67.
  6. Maestroni GJM. “The immunoneuroendocrine raie of melatonin”. Journal of Pineal Research 14 (1993): 1-10.
  7. Kuklina EM., et al. “Raie of melatonin in the regulation of differentiation of Tcell producing interleukin -17 (Th17)”. Bulletin of Experimental Biology and Medicine 160 (2016): 656-658.
  8. Yang B., et al. “The raie of interleukin 17 in tumour proliferation, angiogenesis and metastasis”. Mediators of Inflammation (2014): 623759.
  9. Lissoni P., et al. “Dose-dependency of antitumor effects of the pineal hormone melatonin in untreatable metastatic solid turnar patients”. International Journal of Immunology and Immunotherapy 1 (2018): 104-106.
  10. Mills E., et al. “Melatonin in the treatment cancer: a systematic review of randomized contrailed trials and meta-analysis”. Journal of Pineal Research 39 (2005): 360-366.
  11. Lissoni P., et al. “Five year-survival with high-dose melatonin and other antitumor pineal hormones in advanced cancer patients eligible far the only palliative therapy”. Research Journal of Oncology 2 (2018): 1-7.
  12. Grimm EA., et al. “Lymphokine-activated killer celi phenomenon”. Journal of Experimental Medicine 155 (1982): 1823-1841.
  13. Mantovani A., et al. “Cancer-related inflammation”. Nature 454 (2008): 436-444.
  14. Gu L., et al. “Prognostic role of lymphocyte-to-monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis”. Oncotarget 3 (2016): 7876-7881.
  15. Cao Z., et al. “Active hexose correlateci compound potentiates the antitumor effects of low-dose 5-fluorouracil through modulation of the immune function in hepatoma 22 tumor-bearing mice”. Nutrition Research and Practice 9 (2015): 129-136.
  16.  

Citation

Citation: Carlo Pastore., et al. “A Phase-2 Study of High-dose Melatonin in Association with Active Hexose-correlated Compound (NK-Life) in Advanced Cancer Patients with Persistent Lymphocytopenia".Acta Scientific Medical Sciences 6.10 (2022): 51-53.

Copyright

Copyright: © 2022 Carlo Pastore., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 15, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US